Status:
COMPLETED
Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension
Lead Sponsor:
Pfizer
Conditions:
Hypertension
Blood Pressure, High
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine if there is greater blood pressure reduction using ramipril or hydrochlorothiazide alone or ramipril and hydrochlorothiazide together.
Eligibility Criteria
Inclusion
- Previously diagnosed, or newly diagnosed essential hypertension. Blood pressure must be within a minimum and maximum range prior to drug treatment.
Exclusion
- Inability to discontinue all prior antihypertensive medications
- Heart failure
- History of stroke, myocardial infarction, or chest pain within 3 years, or an abnormal heart rhythm
- Liver or kidney disease
- Certain drugs used to treat other conditions like an enlarged prostate gland, or arthritis
- Allergy or reactions to certain medications used to treat high blood pressure
- Other protocol-defined inclusion and exclusion criteria apply.
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00355589
Start Date
July 1 2006
End Date
March 1 2007
Last Update
October 10 2012
Active Locations (60)
Enter a location and click search to find clinical trials sorted by distance.
1
Cahaba Research Inc.
Birmingham, Alabama, United States, 35242
2
Clinical Research Associates
Huntsville, Alabama, United States, 35801
3
Pulmonary Associates
Glendale, Arizona, United States, 85306
4
Impact Clinical Trials
Beverly Hills, California, United States, 90211